(Adds investment figure)
PARIS, Nov 23 (Reuters) – French President Emmanuel
Macron will on Thursday inaugurate a 2.1 billion euro ($2.3
billion) investment by Danish pharmaceutical company Novo
Nordisk in France, his office said, pitching it as a
sign of newly restored French industrial competitiveness.
The investment, for which no detail was provided by Macron’s
office, will be based in Chartres, west of Paris, where Novo
already employs nearly 2,000 people. Novo is known for its
hugely popular anti-obesity drug Wegovy.
The Elysee palace deemed it the most significant investment
in the health sector of Macron’s mandates so far and said it
would create 500 jobs.
($1 = 0.9168 euros)
(Reporting by Michel Rose, Editing by Dominique Vidalon)